Atossa Therapeutics Inc. (ATOS)
| Bid | 0.62 |
| Market Cap | 80.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.5M |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -3.12 |
| Forward PE | -2.15 |
| Analyst | Buy |
| Ask | 0.62 |
| Volume | 412,399 |
| Avg. Volume (20D) | 638,958 |
| Open | 0.61 |
| Previous Close | 0.60 |
| Day's Range | 0.59 - 0.63 |
| 52-Week Range | 0.55 - 1.81 |
| Beta | 1.47 |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patien...
Analyst Forecast
According to 3 analyst ratings, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 1023.42% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call TranscriptAtossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and...